To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
7 Current news of Sangamo BioSciencesrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Sangamo Therapeutics, Inc. announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” said Sandy Macrae, CEO ...
Sangamo Therapeutics and TxCell announced that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then ...
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. announced a significant alliance focused on the development of high value laboratory research reagents based upon Sangamo's ZFP technology. The alliance combines Sigma's global marketing capabilities and reputation as a provider of high ...
Dow AgroSciences LLC and Sangamo BioSciences, Inc. announced the successful completion of multiple research milestones as part of their Research and Commercial License Agreement initiated October 2005. The three-year agreement provides Dow AgroSciences with access to Sangamo's proprietary zinc ...
Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, and Sangamo BioSciences, Inc. announced the signing of a Research and Commercial License Agreement. The agreement provides Dow AgroSciences with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) ...
Novo Nordisk A/S and Sangamo BioSciences, Inc. announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. Sangamo will provide its ZFP technology for Novo Nordisk to evaluate for use in the field of enhanced protein ...
Third ATP Grant Awarded to Company
Richmond, Calif. -- Sangamo BioSciences, Inc. announced that the company has been awarded an Advanced Technology Program (ATP) grant to conduct research on a novel application of Sangamo's zinc finger DNA binding protein transcription factor (ZFP TF) technology. The grant, worth $2 million, was ...